Person: ÖZGEN, ZÜLEYHA
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
ÖZGEN
First Name
ZÜLEYHA
Name
3 results
Search Results
Now showing 1 - 3 of 3
Publication Metadata only Mesenchymal stem cells derived from human dental follicle modulate the aberrant immune response in atopic dermatitis(FUTURE MEDICINE LTD, 2021) BARIŞ, SAFA; Zibandeh, Noushin; Genc, Deniz; Ozgen, Zuleyha; Duran, Yazgul; Goker, Kamil; Baris, Safa; Ergun, Tulin; Akkoc, TuncBackground: Atopic dermatitis (AD) is an inflammatory cutaneous disorder. The advancements in the understanding of AD immunological pathogenesis have caused the development of therapies that suppress the dysregulated immune response. We aimed to evaluate the immunomodulatory effect of dental stem cells (dental follicle-mesenchymal stem cells [DF-MSCs]) on AD patients. Materials & methods: We investigated the immunoregulatory potential of DF-MSCs on T cell response in AD and compared them with psoriasis and healthy individuals and the underlying mechanisms. Results: DF-MSCs significantly reduced Fas, FasL and TNFR II frequency in T cells, increased naive T cell population while reducing memory T cell, decreased inflammatory cytokine levels and promoted Tregs frequency in the AD population. Conclusion: These results imply that DF-MSCs are modulating inflammation through decreasing T cell apoptosis, inducing Treg expansion and stabilizing cytokine levels. Lay abstract Background: Atopic dermatitis (AD) is an inflammatory cutaneous disorder characterized by immune-mediated inflammation and epidermal barrier dysfunction. There is no definite solution for the treatment of AD. We aimed to evaluate the immunomodulatory and immunosuppressive effect of dental stem cells (dental follicle-mesenchymal stem cell [DF-MSCs]) on AD. Materials & methods: We investigated the immunoregulatory potential of DF-MSCs on inflammatory response in AD and compared them with psoriasis and healthy individuals and the mechanism underlying it. Results: DF-MSCs significantly reduced apoptosis-related markers in immune cells, decreased inflammatory cytokine levels and promoted Treg frequency in the AD. Conclusion: Our findings provide basic evidence for the potential role of DF-MSCs as a cellular therapy option in the treatment of AD and shed light on future clinical studies.Publication Open Access COVID-19 severity and SARS-Cov-2 vaccine safety in pemphigus patients(2022-05-01) ÖZGEN, ZÜLEYHA; ÖZGEN Z., Aksoy H., Cakici O. A., Aksu A. E. K., Erdem O., Polat A. K., Gürel M. S.There are safety concerns in the treatment of pemphigus patients with immunosuppressants, particularly rituximab (RTX), in times of the COVID-19 pandemic. In the beginning, the reports were more pessimistic. However, few reports have recently pointed to manageable courses in this patient group. Therefore, we investigated the disease characteristics and demographic features of pemphigus patients in the period of the COVID-19 pandemic. We aimed to investigate the impact of immunosuppressants on the course of COVID-19 in pemphigus patients. Also, we tried to find out the rate of flares due to COVID-19 and SARS-Cov-2 vaccines. This multicenter study included 247 patients with pemphigus from three tertiary dermatology clinics with the specialized outpatient clinic for autoimmune blistering diseases. Patients were asked standardized questions in person or via telephone calls. Also, demographic data were collected from patients\" files. Two hundred forty-four of 247 patients took the survey between August and September 2021. The data of three patients were obtained from the National Health System. We collected the data of all pemphigus patients who visited the clinics at least once in the past 3 years. Among 51 patients having COVID-19, 40 had a non-serious disease, whereas 11 required hospitalization. One patient died because of COVID-19 infection. The number of patients is limited, and data depends mainly on patients\" statements. RTX treatment does not require additional safety cautions than other immunosuppressives.Publication Open Access Topical cidofovir-related acute kidney injury in a kidney transplant recipient(2022-10-01) VELİOĞLU, ARZU; TİGEN, ELİF; ÖZGEN, ZÜLEYHA; TUĞLULAR, ZÜBEYDE SERHAN; VELİOĞLU A., Erdogan E., TİGEN E., ÖZGEN Z., TUĞLULAR Z. S.